Loading
HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.
HB0036 is an investigational agent whose form is not stated in the registry developed by Shanghai Huaota Biopharmaceutical. Its targets are PD-L1 and TIGIT (the sponsor names PD-L1 x TIGIT). The sponsor states: HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways. ClinicalTrials.gov describes the intervention as: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05417321, plans to enrol 80 participants with primary completion was scheduled for 2025-08-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of HB0036 binds PD-L1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HB0036" OR ABSTRACT:"HB0036" OR TITLE:"Anti-PD-L1 and anti-TIGIT bifunctional molecule" OR ABSTRACT:"Anti-PD-L1 and anti-TIGIT bifunctional molecule") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HB0036, not a curated reading list.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1 and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.